Priority Review Vouchers to Encourage Innovation for Neglected Diseases

Henry G. Grabowski

Seminar Briefing from Office of Health Economics

Abstract: Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for a new drug for one of sixteen tropical diseases, under a law passed in 2007. The PRV entitles the holder to priority review by the FDA of another drug of the bearer’s choice. The Vouchers are transferable, i.e., not limited to use by the company that gained approval of the neglected-disease drug. This Seminar Briefing recounts a presentation by one of the originators of the idea and includes his thoughts on: the potential impact of this incentive on the development of new drugs for neglected disease and how it interacts with other incentives; its possible impact on smaller biotech firms and non-profit drug developers; patients’ access to treatment; financial benefits for firms; and challenges in implementation.

Keywords: Priority; Review; Vouchers; to; Encourage; Innovation; for; Neglected; Diseases (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2011-01-01
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/priority-review-v ... iew-vouchers_1-2011/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:sembri:000193

Access Statistics for this paper

More papers in Seminar Briefing from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).